Previous 10 | Next 10 |
2024-01-04 16:28:54 ET Summary Today, we take a look at Blueprint Medicines Corporation, whose shares have nearly doubled in the past two months due to strong sales of its precision medicine Ayvakit. Ayvakit's label expansion into indolent systemic mastocytosis suggests blockbuste...
2024-01-04 14:57:40 ET More on SPDR S&P Biotech ETF: Biopharmaceutical Stocks: The Rally Has Just Begun Get Ready For The New Biotech Bull Market Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Biotechs p...
2024-01-03 07:00:00 ET Summary The biotech industry experienced a challenging year in 2023 due to a rising 10-year Treasury yield. In 2024, the 10-year yield should favorably support biotech stocks. Promising advancements in weight loss drugs, neuroscience, oncology, and gene ...
2023-12-22 12:00:02 ET Raymond James analyst issues STRONG BUY recommendation for BPMC on December 22, 2023 12:00PM ET. The previous analyst recommendation was Strong Buy. BPMC was trading at $88.13 at issue of the analyst recommendation. The overall analyst consensus : ...
2023-12-21 13:05:16 ET Summary Valuations in the biotech market have fallen, making it a good time for acquisitions in the industry. Investors should focus on commercial-stage biotech companies that generate revenue, as they provide a safety net in uncertain economic conditions. ...
Blueprint Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference PR Newswire CAMBRIDGE, Mass. , Dec. 18, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that Kate Haviland , Chief Executive Officer, will pres...
Blueprint Medicines' AYVAKYT® (avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic Mastocytosis PR Newswire -- In the European Union, patients with indolent systemic mastocytosis now have an approved medicine th...
Blueprint Medicines' Leadership in Driving Continued Innovation in Systemic Mastocytosis Highlighted at 2023 ASH Annual Meeting PR Newswire -- HARBOR Part 1 trial data in indolent systemic mastocytosis showed elenestinib was well-tolerated with broad symptom improvement, suppo...
Blueprint Medicines to Present at JMP Securities Hematology and Oncology Summit PR Newswire CAMBRIDGE, Mass. , Nov. 28, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that company management will participate virtually in a fir...
2023-11-26 07:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
Blueprint Medicines Corporation Company Name:
BPMC Stock Symbol:
NASDAQ Market:
Blueprint Medicines Corporation Website:
2024-05-13 18:15:03 ET Stephens analyst issues OVERWEIGHT recommendation for BPMC on May 13, 2024 04:31PM ET. BPMC was trading at $108.05 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 6 - Buy, 3 - Hold ...
2024-05-09 15:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Jaguar Health Inc. (JAGX) rose 30.3% to $0.2932 on volume of 173,918,707 shares Emergent Biosolutions Inc. (EBS) rose 71.0% to $3.3 on volume of 150,987,238 shares PROSHARES TRUST (SQQQ) fell 3.6% to $11.78 on volume of 136,332,744 sh...